Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 46

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 46
---
the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to
protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person
acting on its behalf shall provide the Investor or its agents or counsel with any information that constitutes material, non-public information
about the Company or its Subsidiaries, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated
by Regulation FD. In the event of a breach of the foregoing covenant by the Company or any Person acting on its behalf (as determined
in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents,
if the Investor is holding any Securities at the time of the disclosure of material, non-public information, the Investor shall have the
right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information
without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, non-public information, the Company shall have at least two (2) Business Days to either
(i) demonstrate that such information is not material non-public information to the reasonable satisfaction of the Investor or (ii) publicly
disclose such material, non-public information prior to any such disclosure by the Investor. The Investor shall not have any liability
to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, shareholders or agents, for any such
disclosure, so long as the Investor has complied with this . The Company understands and confirms that the Investor
shall be relying on the foregoing covenants in effecting transactions in securities of the Company.

(g) . The Investor and the Company shall each maintain records showing the remaining Available Amount at any given time and the
dates and Purchase Amounts for each Fixed Purchase, VWAP Purchase and Additional VWAP Purchase or shall use such other method, reasonably
satisfactory to the Investor and the Company.

(h) Taxes.The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of Depositary Shares to the Investor made under this Agreement. For the avoidance of doubt, any other taxes incurred by the Investor (including any taxes on income resulting from the transactions contemplated by this Agreement) shall solely be the responsibility of the Investor.